BofA raised the firm’s price target on Alnylam to $246 from $239 and keeps a Buy rating on the shares. The company’s management highlighted during its R&D Day confidence in the HELIOS-B readout, the analyst tells investors in a research note. The firm noted that, in its DCF-based model, it adds value for the obesity pipeline, which it sees as a potentially large opportunity.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ALNY:
- Qualcomm downgraded, First Solar upgraded: Wall Street’s top analyst calls
- Alnylam initiated with an Equal Weight at Wells Fargo
- Alnylam initiated with neutral view at Wells Fargo
- Alnylam presents results from KARDIA-1 Phase 2 dose-ranging study of Zilebesiran
- Alnylam price target lowered to $284 from $288 at Canaccord